AXLA Insider Trading Activity and SEC Form 4 Filings
AXLA insider trading summary
No open-market insider purchases or sales of Axcella Health Inc. (AXLA) have been reported on SEC Form 4 in the past 12 months.
Latest AXLA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 1, 2023 | Margaret Koziel | Chief Medical Officer | Sell | $394 (679 @ $0.58) |
| Feb 10, 2023 | Paul Fehlner | SVP & Chief Legal Officer | Sell | $3K (5,221 @ $0.66) |
| Oct 19, 2022 | William Hinshaw | President & CEO | Sell | $25K (16,000 @ $1.56) |
| Oct 13, 2022 | Flagship Ventures Opportunities Fund I, L.P. | 10% Owner | Buy | $1.5M (914,634 @ $1.64) |
| Oct 13, 2022 | Flagship Ventures Opportunities Fund I, L.P. | 10% Owner | Buy | $1.5M (919,111 @ $1.64) |
| Oct 13, 2022 | Noubar Afeyan | 10% Owner | Buy | $4.5M (2,743,902 @ $1.64) |
| Oct 13, 2022 | Flagship Ventures Opportunities Fund I General Partner LLC | 10% Owner | Buy | $4.5M (2,743,902 @ $1.64) |
| Oct 13, 2022 | Flagship Ventures Fund IV, L.P. | 10% Owner | Buy | $4.5M (2,757,333 @ $1.64) |
| Oct 13, 2022 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | Buy | $4.5M (2,743,902 @ $1.64) |
| Oct 13, 2022 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | Buy | $4.5M (2,757,333 @ $1.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.